Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Foamix Pharma Ord (FOMX)

Foamix Pharma Ord (FOMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,130
  • Shares Outstanding, K 61,582
  • Annual Sales, $ 3,600 K
  • Annual Income, $ -74,160 K
  • 60-Month Beta 1.66
  • Price/Sales 139.58
  • Price/Cash Flow N/A
  • Price/Book 3.41
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +384,330.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +3.10%
on 03/06/20
4.69 -36.25%
on 02/07/20
-1.55 (-34.14%)
since 02/06/20
3-Month
2.74 +8.93%
on 12/11/19
4.84 -38.22%
on 01/16/20
-0.07 (-2.29%)
since 12/06/19
52-Week
1.97 +51.78%
on 07/26/19
4.84 -38.22%
on 01/16/20
-0.83 (-21.73%)
since 03/06/19

Most Recent Stories

More News
Actinic (Solar) Keratosis Treatment Market Report 2020-2025 Manufacturers, End Users, Growth, Share and Revenue Analysis

Kenneth Research has published a detailed report on Actinic (Solar) Keratosis Treatment Market which has been categorized by market size, growth indicators and encompasses detailed market analysis on macro...

FOMX : 2.99 (-7.72%)
NVS : 86.10 (+2.51%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 0.7950 (-29.02%)
Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today...

FOMX : 2.99 (-7.72%)
PRGO : 49.01 (+4.10%)
TEVA : 9.79 (+2.62%)
MNLO : 1.0800 (+4.85%)
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020

FOMX : 2.99 (-7.72%)
MNLO : 1.0800 (+4.85%)
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix") following the satisfaction of all...

MNLO : 1.0800 (+4.85%)
FOMX : 2.99 (-7.72%)
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix") following the satisfaction of all...

MNLO : 1.0800 (+4.85%)
FOMX : 2.99 (-7.72%)
Foamix Pharmaceuticals to Present at the Cowen and Company's 40th Annual Health Care Conference

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 2.99 (-7.72%)
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 2.99 (-7.72%)
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 2.99 (-7.72%)
Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder...

FOMX : 2.99 (-7.72%)
MNLO : 1.0800 (+4.85%)
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Studies...

FOMX : 2.99 (-7.72%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More Share

Trade FOMX with:

Business Summary

Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe...

See More

Key Turning Points

2nd Resistance Point 3.65
1st Resistance Point 3.32
Last Price 2.99
1st Support Level 2.78
2nd Support Level 2.57

See More

52-Week High 4.84
Fibonacci 61.8% 3.74
Fibonacci 50% 3.41
Fibonacci 38.2% 3.07
Last Price 2.99
52-Week Low 1.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar